- Home
- TRVN
TRVN
Trevena Inc.
as 07-26-2024 4:00pm EST
Trevena Inc is an American biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CHESTERBROOK |
| Market Cap: | 4.0M | IPO Year: | 2014 |
| Target Price: | $5.00 | AVG Volume (30 days): | 529.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.19 - $1.12 | Next Earning Date: | 08-12-2024 |
| Revenue: | $3,139,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -99.67% | Revenue Growth (next year): | 89400.00% |
Latest Trevena Inc. News
TRVN Breaking Stock News: Dive into TRVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
GlobeNewswire
a month ago
Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models
Associated Press Finance
2 months ago
Trevena: Q1 Earnings Snapshot
GlobeNewswire
2 months ago
Trevena Reports First Quarter 2024 Results and Provides Business Update
Associated Press Finance
4 months ago
Trevena: Q4 Earnings Snapshot
GlobeNewswire
4 months ago
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
GlobeNewswire
6 months ago
BullFrog AI Strengthens Scientific Advisory Board with the Addition of Dr. Gwenn Smith and Dr. Jeremiah Wala
GlobeNewswire
6 months ago
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
Compare TRVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRVN Trevena Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.